Genetic polymorphisms of @entity4433 and XXXX have no influence on esomeprazole treatment for mild @entity2910 .

@entity1 @entity4433 @entity1356 @entity2910 @entity354
@entity1356 is a potent inhibitor of gastric acid secretion and its genetic polymorphism is linked to the severity of @entity354 . Proton-pump inhibitor (PPI) metabolized by P450 2C19 ( @entity4433 ) is the chief medication in @entity354 treatment. The @entity4433 genotype may influence the therapeutic effect of PPI for @entity354 . From November 2009 to June 2012, 184 @entity1 were enrolled in this study with endoscopy examination, 8 weeks of esomeprazole treatment, and 20 weeks of follow-up with questionnaire. These @entity1 also received endoscopy examination after 20 weeks. Blood was collected for genetic polymorphism analysis with polymerase chain reaction. After 8 weeks of treatment with esomeprazole, all of these 184 @entity1 had achieved complete symptom relief. However, in the following 12 weeks, 58.70% (108/184) complained of symptom relapse, 45.65% (84/184) @entity1 had persistent esophageal erosion verified by endoscopy, and in total, 76.09% (140/184) @entity1 had treatment failure at the end of 20 weeks. There were no influences between the genetic polymorphisms of @entity4433 and @entity1356 to treatment failure (p = 0.896). Therefore, prolonging PPI treatment and further lifestyle modification might be warranted for symptomatic mild @entity2910 . There were no relationships between @entity1356 and @entity4433 in the treatment effect in mild @entity354 .
